Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 20170280)

Published in Drug Dev Ind Pharm on March 01, 2010

Authors

Mitalee Tamhane1, Ananthsrinivas R Chakilam, Andrew Jayaraj, Vineet Thakkar, David R Taft

Author Affiliations

1: Division of Pharmaceutical Sciences, Long Island University, Brooklyn, NY 11201, USA.

Articles by these authors

Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release (2004) 1.80

Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol (2009) 1.00

Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res (2007) 0.88

A novel HPLC assay for pentamidine: comparative effects of creatinine and inulin on GFR estimation and pentamidine renal excretion in the isolated perfused rat kidney. J Pharm Pharm Sci (2002) 0.84

Aristolochic acid I metabolism in the isolated perfused rat kidney. Chem Res Toxicol (2011) 0.81

Renal excretion of emtricitabine I: effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion. J Pharm Sci (2008) 0.80

Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem (2006) 0.80

Radioprotective effects of ON 01210.Na upon oral administration. J Radiat Res (2012) 0.78

Characterization of pentamidine excretion in the isolated perfused rat kidney. J Antimicrob Chemother (2003) 0.78

Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. Eur J Pharm Sci (2010) 0.78

Simulation of the pharmacokinetic profile of methazolamide in blood: effect of erythrocyte carbonic anhydrase binding on drug disposition. Pharm Res (2002) 0.77

Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species. Biopharm Drug Dispos (2011) 0.77

Effects of trimethoprim on the clearance of apricitabine, a deoxycytidine analog reverse transcriptase inhibitor, and Lamivudine in the isolated perfused rat kidney. J Pharmacol Exp Ther (2006) 0.77

Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res (2013) 0.76

In vitro evaluation of the release of albuterol sulfate from polymer gels: effect of fatty acids on drug transport across biological membranes. Drug Dev Ind Pharm (2002) 0.75

Renal excretion of emtricitabine II. effect of trimethoprim on emtricitabine excretion: In vitro and in vivo studies. J Pharm Sci (2008) 0.75

Stability of sotalol hydrochloride in extemporaneously prepared oral suspension formulations. Int J Pharm Compd (2013) 0.75

Renal excretion of apricitabine in rats: ex vivo and in vivo studies. Eur J Drug Metab Pharmacokinet (2011) 0.75

Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure. J Pharm Pharmacol (2013) 0.75

Disposition of ON 01210.Na (Ex-RAD(R)), a novel radioprotectant, in the isolated perfused rat liver: probing metabolic inhibition to increase systemic exposure. J Pharm Sci (2012) 0.75

Measuring drug concentrations using pulsatile microdialysis: theory and method development in vitro. Int J Pharm (2005) 0.75

LC/MS/MS plasma assay for the peptidomimetic VLA4 antagonist I and its major active metabolite II: for treatment of asthma by inhalation. J Pharm Biomed Anal (2002) 0.75